US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Wag! Group Co

0.1411

-0.0050-3.42%

Post-market: 0.14370.0026+1.84%19:57 EDT

Volume:680.98K

Turnover:97.23K

Market Cap:7.16M

PE:-0.37

High:0.1460

Open:0.1451

Low:0.1400

Close:0.1461

Loading ...

Overview Company News Filings

National Bank Sticks to Their Buy Rating for Pet Valu Holdings Ltd. (PET)

Clarity Says Imaging Product Shows Superior Results in Phase 2 Trial Versus Standard of Care; Shares Jump 3%

MT Newswires Live

GE Healthcare Says Updated NCCN Guidelines Recommend Use of FES PET Imaging for Breast Cancer

MT Newswires Live

Dongcheng Pharmaceutical Gets Marketing Approval for PET Imaging Agent

MT Newswires Live

Carlit Unit JC Bottling Secures Energy Conservation Subsidy for PET Line Upgrade

MT Newswires Live

Wag Group Q1 EPS $(0.10) Misses $(0.07) Estimate, Sales $15.16M Miss $19.30M Estimate

Press Release: Wag! Reports First Quarter 2025 Results

Malaysian Shares Rebound Midweek Tracking Gains of Regional Markets

MT Newswires Live

Barclays Keeps Their Buy Rating on Pet Valu Holdings Ltd. (PET)

Wag! To Report First Quarter 2025 Financial Results on May 12, 2025

Lantheus Holdings (NasdaqGM:LNTH) Advances Alzheimer's PET Diagnostic With Successful Trial Results

Simply Wall St.

Lantheus Announces Alzheimer’s Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies

RBC Capital Keeps Their Buy Rating on Pet Valu Holdings Ltd. (PET)

Telix Pharmaceuticals Secures Marketing Authorization for Prostate Cancer Imaging Agent in France

MT Newswires Live

Telix's Illuccix PSMA-PET Imaging Agent Approved in France

Wall Street Set to Open Lower Friday Amid Slew of Earnings Reports

MT Newswires Live

Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

Telix Says First Patient Administered Drug Candidate in Trial for Soft Tissue Sarcoma

MT Newswires Live

Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PET/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PET","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PET\",,,,,undefined,":{"symbol":"PET","market":"US","secType":"STK","nameCN":"Wag! Group Co","latestPrice":0.1411,"timestamp":1749240000000,"preClose":0.1461,"halted":0,"volume":680981,"hourTrading":{"tag":"盘后","latestPrice":0.1437,"preClose":0.1411,"latestTime":"19:57 EDT","volume":260613,"amount":38957.068,"timestamp":1749254273439},"delay":0,"floatShares":20337738,"shares":50739113,"eps":-0.384962,"marketStatus":"Market Closed","change":-0.005,"latestTime":"06-06 16:00:00 EDT","open":0.1451,"high":0.146,"low":0.14,"amount":97233.47711602,"amplitude":0.041068,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.384962,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.1461,"preHourTrading":{"tag":"盘前","latestPrice":0.1451,"preClose":0.1461,"latestTime":"09:18 EDT","volume":3139,"amount":455.42128137,"timestamp":1749215909991},"postHourTrading":{"tag":"盘后","latestPrice":0.1437,"preClose":0.1411,"latestTime":"19:57 EDT","volume":260613,"amount":38957.068,"timestamp":1749254273439},"volumeRatio":0.2669937228591776},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PET\",,,,,undefined,":{"symbol":"PET","floatShares":20337738,"roa":"-22.13%","roe":"-3036.82%","lyrEps":-0.392853,"volumeRatio":0.2669937228591776,"shares":50739113,"dividePrice":0,"high":0.146,"amplitude":0.041068,"preClose":0.1461,"low":0.14,"week52Low":0.075,"pbRate":"-2.06","psRate":"0.11","week52High":1.79,"institutionHeld":0,"latestPrice":0.1411,"eps":-0.384962,"divideRate":0,"volume":680981,"delay":0,"ttmEps":-0.384962,"open":0.1451,"prevYearClose":0.2383,"prevWeekClose":0.1537,"prevMonthClose":0.1537,"prevQuarterClose":0.1531,"fiveDayClose":0.1537,"twentyDayClose":0.1484,"sixtyDayClose":0.2447},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PET\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541058041","title":"National Bank Sticks to Their Buy Rating for Pet Valu Holdings Ltd. (PET)","url":"https://stock-news.laohu8.com/highlight/detail?id=2541058041","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541058041?lang=en_us&edition=fundamental","pubTime":"2025-06-05 15:45","pubTimestamp":1749109522,"startTime":"0","endTime":"0","summary":"In a report released today, Vishal Shreedhar from National Bank maintained a Buy rating on Pet Valu Holdings Ltd. (PET – Research Report), with a p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/national-bank-sticks-to-their-buy-rating-for-pet-valu-holdings-ltd-pet-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/national-bank-sticks-to-their-buy-rating-for-pet-valu-holdings-ltd-pet-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PET","NBHC"],"gpt_icon":0},{"id":"2541145960","title":"Clarity Says Imaging Product Shows Superior Results in Phase 2 Trial Versus Standard of Care; Shares Jump 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2541145960","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541145960?lang=en_us&edition=fundamental","pubTime":"2025-06-05 11:05","pubTimestamp":1749092742,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) said results from a phase 2 diagnostic imaging study in patients with known or suspected neuroendocrine tumors showed that lesion detection by copper-64-Sartate outpe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PET.AU","SMP","BK7047","CU6.AU","PET","BK4192","BK7096","XKO.AU","XAO.AU","BK4124","XJO.AU"],"gpt_icon":0},{"id":"2539727846","title":"GE Healthcare Says Updated NCCN Guidelines Recommend Use of FES PET Imaging for Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2539727846","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539727846?lang=en_us&edition=fundamental","pubTime":"2025-05-30 22:01","pubTimestamp":1748613681,"startTime":"0","endTime":"0","summary":"GE Healthcare Technologies  said Friday the NCCN clinical practice guidelines in oncology for doctors now recommend considering the use of fluoroestradiol, or FES, positron emission tomography, or PET, imaging in some individuals with lobular breast cancer.The company said its cerianna injection is the only imaging agent approved by the US Food and Drug Administration to detect estrogen receptor positive breast cancer metastases, including lobular breast cancer.GE Healthcare said invasive lobular cancer is the second most common type of breast cancer in the US.Price: 70.05, Change: -1.48, Percent Change: -2.07","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756168.USD","LU1261432733.SGD","LU0124676726.USD","LU1280957306.USD","BK4192","LU1551013342.USD","BK4187","BK4588","LU2756315318.SGD","BK4137","BK4566","BK4206","LU0943347566.SGD","LU0820561818.USD","LU1988902786.USD","LU0820562030.AUD","LU0354030511.USD","LU1093756325.SGD","LU0354030438.USD","GEHC","LU0820561909.HKD","LU1366192091.USD","LU1064131342.USD","LU1551013425.SGD","LU0689472784.USD","PET","LU2543165471.USD","BK4082","LU0689626769.HKD","BK4585","HCSG","LU2264538146.SGD","LU0640476718.USD","LU0149725797.USD","BK4501","GE","LU0868494617.USD","LU2756315664.SGD","LU0157215616.USD","BK4543","LU1366333091.USD"],"gpt_icon":0},{"id":"2538446827","title":"Dongcheng Pharmaceutical Gets Marketing Approval for PET Imaging Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2538446827","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538446827?lang=en_us&edition=fundamental","pubTime":"2025-05-28 13:49","pubTimestamp":1748411380,"startTime":"0","endTime":"0","summary":"Yantai Dongcheng Pharmaceutical Group  received marketing approval from China's drug administrator for its fluorine [18F] sodium fluoride injection.This PET imaging agent is used to detect bone metastases in breast, prostate and lung cancers, according to a Wednesday filing with the Shenzhen bourse.Shares of the pharmaceutical company rose 1% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4192","BK0239","002675","PET"],"gpt_icon":0},{"id":"2538810562","title":"Carlit Unit JC Bottling Secures Energy Conservation Subsidy for PET Line Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2538810562","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538810562?lang=en_us&edition=fundamental","pubTime":"2025-05-26 20:08","pubTimestamp":1748261336,"startTime":"0","endTime":"0","summary":"Carlit Holdings'  consolidated subsidiary, JC Bottling, has been awarded a subsidy of up to 1.01 billion yen for energy-saving upgrades to its PET bottle manufacturing line in Gunma, Japan, according to a Friday Tokyo bourse filing.The grant, awarded under the Energy Conservation Investment Promotion and Demand Structure Transformation Support Project, will support the installation of an aseptic filling system, heat recovery from high-temperature water, and energy management via Azbil Corp., the filing said.The project is scheduled for completion in December 2026, Carlit said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PET"],"gpt_icon":0},{"id":"2534225977","title":"Wag Group Q1 EPS $(0.10) Misses $(0.07) Estimate, Sales $15.16M Miss $19.30M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2534225977","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534225977?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:02","pubTimestamp":1747047740,"startTime":"0","endTime":"0","summary":"Wag Group (NASDAQ:PET) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 9.09 percent increase over losses of $(0.11) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/05/45343649/wag-group-q1-eps-0-10-misses-0-07-estimate-sales-15-16m-miss-19-30m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PET"],"gpt_icon":0},{"id":"2534426223","title":"Press Release: Wag! Reports First Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2534426223","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534426223?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:00","pubTimestamp":1747047600,"startTime":"0","endTime":"0","summary":"\"; Nasdaq: PET), which strives to be the number one platform to solve the service, product, and wellness needs of the modern U.S. pet household, today announced financial results for the first quarter ended March 31, 2025.-- Revenues of $15.2 million, compared to $23.2 million in the first quarter. of 2024 -- comprised of $4.9 million of Services revenue, $9.2 million of. Wellness revenue, and $1.1 million of Pet Food & Treats revenue.-- Net loss was $4.9 million, compared to $4.2 million in the first quarter. EBITDA of $0.2 million in the first quarter of 2024.\"We are pleased to begin 2025 with results slightly ahead of our expectations on profitability and in line with expectations on revenue,\" said Garrett Smallwood, CEO and Chairman of Wag!. \"This quarter's performance reflects the benefits of our disciplined cost management, operational streamlining and continued focus on higher-return initiatives. We're also encouraged by the early traction we're seeing from our newly launched di","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4192","PET"],"gpt_icon":0},{"id":"2533603382","title":"Malaysian Shares Rebound Midweek Tracking Gains of Regional Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2533603382","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533603382?lang=en_us&edition=fundamental","pubTime":"2025-05-07 17:44","pubTimestamp":1746611072,"startTime":"0","endTime":"0","summary":"Malaysian shares ended in the green on Wednesday, tracking regional gains. The investor interest rebounded amid easing trade tensions.The FTSE Bursa Malaysia KLCI, the main gauge of Malaysian stocks, gained 13.10 points, to end 0.85% higher at 1,549.90. The day range was between 1,536.56 and 1,549.90.Malaysia officially imposed definitive anti-dumping duties on imports of Polyethylene Terephthalate  from China-ranging between 2.29% and 11.74%, and from Indonesia at 37.44%, effective immediately. The Ministry of Investment, Trade and Industry  said the decision follows the conclusion of its months-long probe into alleged unfair trade practices.In corporate news, shares of Malaysian Genomics Resource Center  dropped 6% after its chief operating officer Muhammad Badri Bin Hussin resigned on Monday, May 5, citing personal commitment.Shares of Able Global  gained over 3% after Glass Lewis issued a controversy alert ahead of the company's May 27 annual meeting, citing serious ESG-related gov","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","MITI","BK4192","PET.AU","BK7047","PET"],"gpt_icon":0},{"id":"2533423622","title":"Barclays Keeps Their Buy Rating on Pet Valu Holdings Ltd. (PET)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533423622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533423622?lang=en_us&edition=fundamental","pubTime":"2025-05-07 15:19","pubTimestamp":1746602343,"startTime":"0","endTime":"0","summary":"Barclays analyst Adrienne Yih maintained a Buy rating on Pet Valu Holdings Ltd. (PET – Research Report) today and set a price target of C$32.00. Yi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-buy-rating-on-pet-valu-holdings-ltd-pet-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-buy-rating-on-pet-valu-holdings-ltd-pet-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PET"],"gpt_icon":0},{"id":"2532082880","title":"Wag! To Report First Quarter 2025 Financial Results on May 12, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532082880","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532082880?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:05","pubTimestamp":1746129900,"startTime":"0","endTime":"0","summary":"Group Co., (the “Company” or “Wag!”, Nasdaq: PET), which strives to be the number one platform to solve the service, product, and wellness needs of the modernU.S.pet household, today announced that it will report first quarter 2025 financial results before market open on Monday, May 12, 2025. The Company will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results.Group Co.strives to be the number one platform to solve the service, product, and wellness needs of the modernU.S.pet household. Wag!pioneered on-demand dog walking in 2015 with the Wag!app, which offers access to 5-star dog walking, sitting, and one-on-one training from a community of over 500,000 Pet Caregivers nationwide. In addition,Wag!Group Co.operatesPetted, one of the nation’s largest pet insurance comparison marketplaces;Dog Food Advisor, one of the most visited and trusted pet food review platforms;WoofWoofTV, a multi-media company bringing delightful pet content to over 18 million follower","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wag-report-first-quarter-2025-200500655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PET","PETWW"],"gpt_icon":0},{"id":"2532918889","title":"Lantheus Holdings (NasdaqGM:LNTH) Advances Alzheimer's PET Diagnostic With Successful Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532918889","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532918889?lang=en_us&edition=fundamental","pubTime":"2025-05-02 02:12","pubTimestamp":1746123120,"startTime":"0","endTime":"0","summary":"Lantheus Holdings announced clinical success with its MK-6240 PET radiodiagnostic, showing promise in Alzheimer’s detection, and plans an NDA submission to the FDA. Over the last quarter, Lantheus experienced a 13% price increase, likely supported by positive trial results and broader market resilience. Its earnings report reflected increased sales but lower net income, offering mixed signals. The S&P 500 and Nasdaq have been performing robustly, with strong earnings from tech giants enhancing investor sentiment. Lantheus’s clinical advancements align with these positive trends, potentially fortifying investor confidence in the company's long-term potential.View our complete analysis and fair value estimate and you decide.NasdaqGM:LNTH Revenue & Expenses Breakdown as at May 2025. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial ad","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lantheus-holdings-nasdaqgm-lnth-advances-181200104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4192","BK4588","LNTH","PET","BK4198","BK4585"],"gpt_icon":0},{"id":"2531303233","title":"Lantheus Announces Alzheimer’s Disease Radiodiagnostic MK-6240 Meets Co-Primary Endpoints in Two Pivotal Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2531303233","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531303233?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:30","pubTimestamp":1746016200,"startTime":"0","endTime":"0","summary":"Company plans to file NDA in the third quarter of this year. “The clinical results of MK-6240 underscore our commitment to providing cutting-edge imaging solutions for Alzheimer’s disease that align with the latest scientific advancements,” said Brian Markison, CEO, Lantheus. “With MK-6240 successfully meeting its primary endpoints in both pivotal studies, we are moving closer to delivering this innovative radiodiagnostic to potentially support precise diagnoses and improve disease management.”Driven by rising prevalence, more treatment options, and expanded PET imaging guidelines, the U.S. Alzheimer’s Disease radiodiagnostic market has the potential to reach over 400,000 scans and $1.5 billion by 2030","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lantheus-announces-alzheimer-disease-radiodiagnostic-123000597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LNTH","BK4585","PET","BK4588","BK4192","BK4198"],"gpt_icon":0},{"id":"2531854287","title":"RBC Capital Keeps Their Buy Rating on Pet Valu Holdings Ltd. (PET)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531854287","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531854287?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:50","pubTimestamp":1745923810,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Irene Nattel from RBC Capital reiterated a Buy rating on Pet Valu Holdings Ltd. (PET – Research Report), with a pri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-pet-valu-holdings-ltd-pet-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-keeps-their-buy-rating-on-pet-valu-holdings-ltd-pet-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PET"],"gpt_icon":0},{"id":"2531291299","title":"Telix Pharmaceuticals Secures Marketing Authorization for Prostate Cancer Imaging Agent in France","url":"https://stock-news.laohu8.com/highlight/detail?id=2531291299","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531291299?lang=en_us&edition=fundamental","pubTime":"2025-04-29 07:49","pubTimestamp":1745884196,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  received marketing authorization in France for Illuccix, its prostate cancer positron emission tomography  imaging agent, the company said in a statement Monday.Illucix is indicated in France for the detection and localization of prostate-specific membrane antigen-positive lesions in adults with prostate cancer, the statement said.The company is partnering with IRE Group subsidiary IRE ELiT to market and promote Illuccix in France, according to the statement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7047","PET.AU","BK7067","TLX","PET","BK4192","TLX.AU"],"gpt_icon":0},{"id":"2531999262","title":"Telix's Illuccix PSMA-PET Imaging Agent Approved in France","url":"https://stock-news.laohu8.com/highlight/detail?id=2531999262","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531999262?lang=en_us&edition=fundamental","pubTime":"2025-04-29 06:30","pubTimestamp":1745879400,"startTime":"0","endTime":"0","summary":"New approval provides French hospitals and clinics with access to a provenPSMA-PET imaging agent. MELBOURNE, Australia, April 29, 2025  -- Telix Pharmaceuticals Limited  today announces that its prostate cancer PET1 imaging agent, Illuccix , has been granted marketing authorization in France by ANSM2 for the detection and localization of prostate-specific membrane antigen -positive lesions in adults with prostate cancer, a broad clinical label.Illuccix, after radiolabelling with gallium-68, is indicated in France for the detection of prostate-specific membrane antigen -positive lesions with PET in adults with prostate cancer  in the following clinical settings:. Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer  for whom PSMA-targeted therapy is indicated.With its broad indication and ready-to-use formulation, Illuccix is designed to support healthcare providers in delivering efficient and reliable imaging. The approval comes as d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telixs-illuccix-psma-pet-imaging-223000028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","BK4233","BK4109","BK4217","UK","TLX","BK4528","BK4543","TGA","TLX.AU","BK4205","BK4084","BK4141","PET","DCP","ASX","BCR","BK4526","BK4585","BK4533","PSA","BK4588","CE","BK4139","EEA","BK4144","BK4192"],"gpt_icon":0},{"id":"2530613504","title":"Wall Street Set to Open Lower Friday Amid Slew of Earnings Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2530613504","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530613504?lang=en_us&edition=fundamental","pubTime":"2025-04-25 21:18","pubTimestamp":1745587126,"startTime":"0","endTime":"0","summary":"Group  lost 19%, eating half of Thursday's 38% gain.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OMEX","INTS","PET","SES","CIA","BCTX","PONY","SAIA"],"gpt_icon":1},{"id":"2528748056","title":"Clarity signs high-volume commercial-scale copper-64 Supply Agreement with Nusano","url":"https://stock-news.laohu8.com/highlight/detail?id=2528748056","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528748056?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:01","pubTimestamp":1744894860,"startTime":"0","endTime":"0","summary":"Clarity has signed a commercial-scale agreement withNusano, Inc.  for supply of copper-64  isotope.The 190,000 square footNusano facility in West Valley City, Utah is capable of producing more than 1,000 Ci  of copper-64 per day at capacity, which translates into more than 18,000 patient doses per day at 200 MBq per dose, with a 48-hour shelf-life, far in excess of commercial scale demands across multiple large indications.Clarity's Executive Chairperson, Dr Alan Taylor, commented, \"The signing of this Supply Agreement with Nusano will complement Clarity's existing network of US-based copper-64 suppliers, providing capacity to ensure abundant and seamless supply of the isotope. As Clarity is generating exceptional data in a number of late-stage clinical trials, we now also have a cost-effective, large-scale supply strategy locked in for the commercial roll-out of our Targeted Copper Theranostics  in the largest healthcare market in the world, the US. This Agreement is an important part","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/clarity-signs-high-volume-commercial-130100382.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-signs-high-volume-commercial-130100382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["PET.AU","BK7096","CU6.AU","BK4192","BK7047","PET"],"gpt_icon":0},{"id":"2524146431","title":"Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2524146431","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524146431?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:30","pubTimestamp":1743593400,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April 02, 2025  -- Biogen Inc.  today announced that the U.S. Food and Drug Administration  has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide  therapy targeting tau, for the treatment of Alzheimer’s disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs.About BIIB080BIIB080 is an investigational antisense oligonucleotide  therapy designed to target microtubule-associated protein tau  mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer’s disease and is associated with neurodegeneration and cognitive decline. BIIB080 is currently being evaluated in a Phase 2 clinical study  in individuals with early Alzheimer’s disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biogen-investigational-tau-targeting-therapy-113000529.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4192","BK4561","MAPT","BK4104","LU0889565916.HKD","BK4533","IE00B19Z9Z06.USD","LU0320765992.SGD","BK4532","IE00BYQQ9H92.USD","IE00BFXG0V08.USD","BK4023","FAST","BK4567","LU0109394709.USD","ASO","IE00B19Z9P08.USD","BIIB","IE00B894F039.SGD","PET","BK4200","BK4588","CSF","BK4585","LU0234570918.USD","IE00B5TLWC47.USD"],"gpt_icon":0},{"id":"2524818124","title":"Telix Says First Patient Administered Drug Candidate in Trial for Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2524818124","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524818124?lang=en_us&edition=fundamental","pubTime":"2025-04-02 13:19","pubTimestamp":1743571140,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said the first patient has been administered its drug candidate TLX300-CDx in the Phase 1 ZOLAR1 trial for advanced metastatic soft tissue sarcoma , according to a Tuesday statement by the company.The trial aims to assess the drug's biodistribution, safety, and optimal dose using positron emission tomography , the statement said.TLX300-CDx targets PDGFRα, a protein often over-expressed in STS, the statement added.The study will inform future therapeutic approaches for treating the disease, the company said.Telix holds the rights to develop and commercialize the radiolabelled drug, the company added.Shares of the company fell 3% on market close.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","PET","BK7047","PET.AU","BK7067","BK4192"],"gpt_icon":0},{"id":"2524126511","title":"Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2524126511","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524126511?lang=en_us&edition=fundamental","pubTime":"2025-04-02 03:30","pubTimestamp":1743535800,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, April 02, 2025  -- Telix Pharmaceuticals Limited  today announces that a first patient has been dosed in the Phase 1 ZOLAR1 trial of TLX300-CDx  in patients with advanced, metastatic soft tissue sarcoma  at the Melbourne Theranostic Innovation Centre  in Melbourne, Australia.The aim of the trial is to evaluate the safety, pharmacokinetics, biodistribution and dosimetry, and establish the optimal dose of TLX300-CDx in patients with advanced STS, prior to therapeutic studies, based on a theranostic approach. As part of the study, it is also expected that the patient dosimetry and target expression characteristics will inform the final selection of therapeutic radionuclide for this candidate, in conjunction with currently active non-clinical radiation biology studies.Telix intends to develop a novel targeted radionuclide therapy, specific for PDGFRα, which could be used to treat patients with STS. Telix holds the exclusive worldwide rights to develop and commercializ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telix-announces-first-patient-dosed-193000667.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["IE00B66KJ199.SGD","XJO.AU","PET","XKO.AU","BK4139","BK7047","BK4543","BK4192","IE0031619046.USD","BK4526","AEIS","BK7039","TLX.AU","IE00B7SZL793.SGD","SEC.AU","BK4157","BK4141","TLX","ASX","PET.AU","BK7067","XAO.AU","IE00B19Z4B17.USD","ASX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":94,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PET\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-12","symbol":"PET","fiscalQuarterEnding":"2025/03","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.1},{"market":"US","date":"2025-03-24","symbol":"PET","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742788800000,"reportTimeType":"pre","actualEps":-0.1},{"market":"US","date":"2024-11-13","symbol":"PET","fiscalQuarterEnding":"2024/09","expectedEps":-0.04,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"pre","actualEps":-0.13},{"market":"US","date":"2024-08-07","symbol":"PET","fiscalQuarterEnding":"2024/06","expectedEps":-0.06,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.06},{"date":"2024-07-10","symbol":"PET","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1720598400000,"name":null,"time":"Pre-Market","dateTimestamp":1720584000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PET\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PET\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1731643200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PET\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PET","date":"2025-06-06","current":-0.406927,"percent":0.970556,"low":-51.918761,"twenty":-24.534246,"median":-3.83968,"eighty":-1.76216,"high":-0.269148,"avg":-9.753644,"sd":10.80954,"marketCap":7412984},"quantilePoints":[{"date":"2021-10-01","current":-7.916755,"twenty":-7.916755,"median":-7.908627,"eighty":-7.901458,"marketCap":149143750},{"date":"2021-10-08","current":-7.941139,"twenty":-7.942895,"median":-7.928947,"eighty":-7.908627,"marketCap":149603125},{"date":"2021-10-15","current":-7.900499,"twenty":-7.941172,"median":-7.916755,"eighty":-7.900499,"marketCap":148837500},{"date":"2021-10-22","current":-7.908627,"twenty":-7.941139,"median":-7.908627,"eighty":-7.900499,"marketCap":148990625},{"date":"2021-10-29","current":-7.908627,"twenty":-7.934637,"median":-7.908627,"eighty":-7.900499,"marketCap":148990625},{"date":"2021-11-05","current":-7.941139,"twenty":-7.941139,"median":-7.916755,"eighty":-7.900499,"marketCap":149603125},{"date":"2021-11-12","current":-7.949267,"twenty":-7.941139,"median":-7.924883,"eighty":-7.907001,"marketCap":149756250},{"date":"2021-11-19","current":-7.965524,"twenty":-7.949267,"median":-7.933011,"eighty":-7.908627,"marketCap":150062500},{"date":"2021-11-26","current":-8.185579,"twenty":-7.949267,"median":-7.933011,"eighty":-7.908627,"marketCap":154208125},{"date":"2021-12-03","current":-8.143943,"twenty":-7.965524,"median":-7.941139,"eighty":-7.908627,"marketCap":153423750},{"date":"2021-12-10","current":-8.110635,"twenty":-8.123958,"median":-7.941139,"eighty":-7.908627,"marketCap":152796250},{"date":"2021-12-17","current":-8.111634,"twenty":-8.143943,"median":-7.941139,"eighty":-7.908627,"marketCap":152815075},{"date":"2021-12-23","current":-8.135616,"twenty":-8.143943,"median":-7.949267,"eighty":-7.908627,"marketCap":153266875},{"date":"2021-12-31","current":-8.143943,"twenty":-8.143943,"median":-7.949267,"eighty":-7.911878,"marketCap":153423750},{"date":"2022-01-07","current":-25.77251,"twenty":-8.143943,"median":-7.957396,"eighty":-7.916755,"marketCap":153423750},{"date":"2022-01-14","current":-25.746157,"twenty":-8.168925,"median":-7.965524,"eighty":-7.916755,"marketCap":153266875},{"date":"2022-01-21","current":-25.746157,"twenty":-8.185579,"median":-7.977716,"eighty":-7.918381,"marketCap":153266875},{"date":"2022-01-28","current":-25.746157,"twenty":-25.693453,"median":-8.111634,"eighty":-7.924883,"marketCap":153266875},{"date":"2022-02-04","current":-25.825214,"twenty":-25.746157,"median":-8.115298,"eighty":-7.926509,"marketCap":153737500},{"date":"2022-02-11","current":-25.956975,"twenty":-25.746157,"median":-8.135616,"eighty":-7.933011,"marketCap":154521875},{"date":"2022-02-18","current":-25.904271,"twenty":-25.746157,"median":-8.143943,"eighty":-7.933011,"marketCap":154208125},{"date":"2022-02-25","current":-25.851566,"twenty":-25.77251,"median":-8.143943,"eighty":-7.933011,"marketCap":153894375},{"date":"2022-03-04","current":-25.930623,"twenty":-25.77251,"median":-8.143943,"eighty":-7.933011,"marketCap":154365000},{"date":"2022-03-11","current":-25.956975,"twenty":-25.825214,"median":-8.143943,"eighty":-7.941139,"marketCap":154521875},{"date":"2022-03-18","current":-26.115089,"twenty":-25.825214,"median":-8.160598,"eighty":-7.941139,"marketCap":155463125},{"date":"2022-03-25","current":-26.036032,"twenty":-25.851566,"median":-8.177252,"eighty":-7.941139,"marketCap":154992500},{"date":"2022-04-01","current":-26.036032,"twenty":-25.877919,"median":-8.185579,"eighty":-7.941139,"marketCap":154992500},{"date":"2022-04-08","current":-26.036032,"twenty":-25.904271,"median":-16.939516,"eighty":-7.941139,"marketCap":154992500},{"date":"2022-04-14","current":-26.220498,"twenty":-25.956975,"median":-25.700041,"eighty":-7.941139,"marketCap":156090625},{"date":"2022-04-22","current":-26.036032,"twenty":-25.956975,"median":-25.746157,"eighty":-7.941139,"marketCap":154992500},{"date":"2022-04-29","current":-26.088737,"twenty":-26.00968,"median":-25.746157,"eighty":-7.941269,"marketCap":155306250},{"date":"2022-05-06","current":-26.036032,"twenty":-26.01495,"median":-25.746157,"eighty":-7.947674,"marketCap":154992500},{"date":"2022-05-13","current":-24.509388,"twenty":-26.01495,"median":-25.746157,"eighty":-7.949267,"marketCap":154678750},{"date":"2022-05-20","current":-24.534246,"twenty":-26.00968,"median":-25.746157,"eighty":-7.949267,"marketCap":154835625},{"date":"2022-05-27","current":-24.68339,"twenty":-26.00968,"median":-25.719805,"eighty":-7.949267,"marketCap":155776875},{"date":"2022-06-03","current":-24.68339,"twenty":-26.00968,"median":-25.693453,"eighty":-7.949267,"marketCap":155776875},{"date":"2022-06-10","current":-24.583961,"twenty":-26.00968,"median":-24.68339,"eighty":-7.954144,"marketCap":155149375},{"date":"2022-06-17","current":-24.608818,"twenty":-26.00968,"median":-24.68339,"eighty":-7.957396,"marketCap":155306250},{"date":"2022-06-24","current":-24.708248,"twenty":-25.988598,"median":-24.68339,"eighty":-7.960647,"marketCap":155933750},{"date":"2022-07-01","current":-24.608818,"twenty":-25.956975,"median":-24.658533,"eighty":-7.965524,"marketCap":155306250},{"date":"2022-07-08","current":-24.733105,"twenty":-25.956975,"median":-24.658533,"eighty":-7.96715,"marketCap":156090625},{"date":"2022-07-15","current":-24.757962,"twenty":-25.956975,"median":-24.68339,"eighty":-7.975278,"marketCap":156247500},{"date":"2022-07-22","current":-24.807677,"twenty":-25.956975,"median":-24.68339,"eighty":-8.007551,"marketCap":156561250},{"date":"2022-07-29","current":-25.105966,"twenty":-25.956975,"median":-24.68339,"eighty":-8.110835,"marketCap":158443750},{"date":"2022-08-05","current":-19.587625,"twenty":-25.956975,"median":-24.68339,"eighty":-8.111634,"marketCap":123617500},{"date":"2022-08-12","current":-46.571248,"twenty":-25.956975,"median":-24.68339,"eighty":-8.111634,"marketCap":293911149},{"date":"2022-08-19","current":-31.187311,"twenty":-26.00968,"median":-24.68339,"eighty":-8.1131,"marketCap":196823120},{"date":"2022-08-26","current":-29.685032,"twenty":-26.00968,"median":-24.708248,"eighty":-8.118962,"marketCap":187342238},{"date":"2022-09-02","current":-34.550721,"twenty":-26.036032,"median":-24.733105,"eighty":-8.122293,"marketCap":159278826},{"date":"2022-09-09","current":-42.365766,"twenty":-26.036032,"median":-24.757962,"eighty":-8.135616,"marketCap":195306179},{"date":"2022-09-16","current":-44.175565,"twenty":-26.036032,"median":-24.78282,"eighty":-8.135616,"marketCap":203649356},{"date":"2022-09-23","current":-20.154587,"twenty":-26.036032,"median":-24.78282,"eighty":-8.143943,"marketCap":92912648},{"date":"2022-09-30","current":-16.864043,"twenty":-26.036032,"median":-24.745534,"eighty":-8.143943,"marketCap":77743236},{"date":"2022-10-07","current":-20.812696,"twenty":-26.036032,"median":-24.733105,"eighty":-8.143943,"marketCap":95946530},{"date":"2022-10-14","current":-24.020978,"twenty":-26.036032,"median":-24.708248,"eighty":-8.143943,"marketCap":110736707},{"date":"2022-10-21","current":-32.45159,"twenty":-26.036032,"median":-24.733105,"eighty":-8.143943,"marketCap":149601831},{"date":"2022-10-28","current":-34.873351,"twenty":-26.036032,"median":-24.745534,"eighty":-8.143943,"marketCap":160766146},{"date":"2022-11-04","current":-27.317458,"twenty":-26.115089,"median":-24.78282,"eighty":-8.143943,"marketCap":125933481},{"date":"2022-11-11","current":-2.304056,"twenty":-26.115089,"median":-24.78282,"eighty":-8.143943,"marketCap":108509519},{"date":"2022-11-18","current":-2.038504,"twenty":-26.115089,"median":-24.757962,"eighty":-8.143943,"marketCap":96003337},{"date":"2022-11-25","current":-1.9604,"twenty":-26.115089,"median":-24.733105,"eighty":-8.132285,"marketCap":92325048},{"date":"2022-12-02","current":-1.991642,"twenty":-26.094007,"median":-24.708248,"eighty":-8.111634,"marketCap":93796364},{"date":"2022-12-09","current":-1.62846,"twenty":-26.046573,"median":-24.68339,"eighty":-7.972026,"marketCap":76692321},{"date":"2022-12-16","current":-1.679227,"twenty":-26.036032,"median":-24.68339,"eighty":-7.95577,"marketCap":79083209},{"date":"2022-12-23","current":-2.436832,"twenty":-26.036032,"median":-24.658533,"eighty":-7.949267,"marketCap":114762610},{"date":"2022-12-30","current":-2.405591,"twenty":-26.036032,"median":-24.658533,"eighty":-7.941139,"marketCap":113291295},{"date":"2023-01-06","current":-2.069667,"twenty":-26.036032,"median":-24.633675,"eighty":-7.941139,"marketCap":97470974},{"date":"2023-01-13","current":-2.218142,"twenty":-26.036032,"median":-24.621246,"eighty":-7.933011,"marketCap":104463401},{"date":"2023-01-20","current":-2.17128,"twenty":-26.036032,"median":-24.608818,"eighty":-7.926509,"marketCap":102256428},{"date":"2023-01-27","current":-2.530556,"twenty":-26.036032,"median":-24.608818,"eighty":-7.916755,"marketCap":119176557},{"date":"2023-02-03","current":-2.155659,"twenty":-26.036032,"median":-24.608818,"eighty":-7.908627,"marketCap":101520770},{"date":"2023-02-10","current":-1.851055,"twenty":-26.036032,"median":-24.608818,"eighty":-7.902125,"marketCap":87175444},{"date":"2023-02-17","current":-1.874486,"twenty":-26.036032,"median":-24.571532,"eighty":-7.893997,"marketCap":88278931},{"date":"2023-02-24","current":-2.245322,"twenty":-26.036032,"median":-24.559103,"eighty":-2.530556,"marketCap":86595328},{"date":"2023-03-03","current":-2.245322,"twenty":-26.036032,"median":-24.534246,"eighty":-2.452453,"marketCap":86595328},{"date":"2023-03-10","current":-1.614721,"twenty":-26.036032,"median":-24.534246,"eighty":-2.413401,"marketCap":62274938},{"date":"2023-03-17","current":-1.94913,"twenty":-26.036032,"median":-24.534246,"eighty":-2.38997,"marketCap":75172115},{"date":"2023-03-24","current":-2.197549,"twenty":-26.036032,"median":-24.509388,"eighty":-2.340867,"marketCap":84752874},{"date":"2023-03-31","current":-2.140222,"twenty":-26.036032,"median":-24.020978,"eighty":-2.293095,"marketCap":82541930},{"date":"2023-04-06","current":-2.111558,"twenty":-26.036032,"median":-23.445132,"eighty":-2.245322,"marketCap":81436457},{"date":"2023-04-14","current":-2.159331,"twenty":-26.036032,"median":-22.561,"eighty":-2.225952,"marketCap":83278911},{"date":"2023-04-21","current":-2.203009,"twenty":-26.01495,"median":-21.964387,"eighty":-2.217056,"marketCap":84963432},{"date":"2023-04-28","current":-2.270943,"twenty":-26.00968,"median":-20.697308,"eighty":-2.210332,"marketCap":87583450},{"date":"2023-05-05","current":-2.021661,"twenty":-26.00968,"median":-19.99006,"eighty":-2.209686,"marketCap":77969386},{"date":"2023-05-12","current":-2.248784,"twenty":-26.00968,"median":-19.907797,"eighty":-2.209686,"marketCap":89960352},{"date":"2023-05-19","current":-2.248784,"twenty":-26.00968,"median":-19.587625,"eighty":-2.209686,"marketCap":89960352},{"date":"2023-05-26","current":-1.874257,"twenty":-26.00968,"median":-19.301764,"eighty":-2.197549,"marketCap":74977784},{"date":"2023-06-02","current":-2.174138,"twenty":-25.978057,"median":-18.097997,"eighty":-2.197549,"marketCap":86974229},{"date":"2023-06-09","current":-2.061683,"twenty":-25.956975,"median":-16.864043,"eighty":-2.186237,"marketCap":82475562},{"date":"2023-06-16","current":-2.127282,"twenty":-25.956975,"median":-8.185579,"eighty":-2.180933,"marketCap":85099784},{"date":"2023-06-23","current":-2.04294,"twenty":-25.956975,"median":-8.185579,"eighty":-2.17128,"marketCap":81725784},{"date":"2023-06-29","current":-1.958599,"twenty":-25.956975,"median":-8.185579,"eighty":-2.164767,"marketCap":78351784},{"date":"2023-07-07","current":-1.883628,"twenty":-25.956975,"median":-8.168925,"eighty":-2.16347,"marketCap":75352672},{"date":"2023-07-14","current":-1.893,"twenty":-25.956975,"median":-8.148107,"eighty":-2.155659,"marketCap":75727561},{"date":"2023-07-21","current":-2.04294,"twenty":-25.956975,"median":-8.143943,"eighty":-2.147849,"marketCap":81725784},{"date":"2023-07-28","current":-2.108539,"twenty":-25.956975,"median":-8.143943,"eighty":-2.139508,"marketCap":84350007},{"date":"2023-08-04","current":-2.267851,"twenty":-25.941164,"median":-8.143943,"eighty":-2.138794,"marketCap":90723118},{"date":"2023-08-11","current":-2.32208,"twenty":-25.920074,"median":-8.135616,"eighty":-2.137501,"marketCap":99345563},{"date":"2023-08-18","current":-2.075795,"twenty":-25.907779,"median":-8.118962,"eighty":-2.137501,"marketCap":88808739},{"date":"2023-08-25","current":-2.053134,"twenty":-25.904271,"median":-8.111634,"eighty":-2.127997,"marketCap":87839211},{"date":"2023-09-01","current":-1.840115,"twenty":-25.904271,"median":-8.046207,"eighty":-2.121113,"marketCap":78725651},{"date":"2023-09-08","current":-1.903567,"twenty":-25.903322,"median":-7.973652,"eighty":-2.112829,"marketCap":81440328},{"date":"2023-09-15","current":-1.758534,"twenty":-25.899527,"median":-7.965524,"eighty":-2.108539,"marketCap":75235351},{"date":"2023-09-22","current":-1.695082,"twenty":-25.877919,"median":-7.953331,"eighty":-2.093176,"marketCap":72520673},{"date":"2023-09-29","current":-1.740405,"twenty":-25.851566,"median":-7.949267,"eighty":-2.080425,"marketCap":74459729},{"date":"2023-10-06","current":-1.704146,"twenty":-25.851566,"median":-7.945284,"eighty":-2.069745,"marketCap":72908484},{"date":"2023-10-13","current":-1.676952,"twenty":-25.851566,"median":-7.941139,"eighty":-2.061683,"marketCap":71745051},{"date":"2023-10-20","current":-1.60933,"twenty":-25.851566,"median":-7.941139,"eighty":-2.052312,"marketCap":68851980},{"date":"2023-10-27","current":-1.568177,"twenty":-25.851566,"median":-7.941139,"eighty":-2.045204,"marketCap":67091318},{"date":"2023-11-03","current":-1.560563,"twenty":-25.851566,"median":-7.933011,"eighty":-2.038504,"marketCap":66765557},{"date":"2023-11-10","current":-16.478139,"twenty":-25.851566,"median":-7.933011,"eighty":-2.036475,"marketCap":66703507},{"date":"2023-11-17","current":-17.055401,"twenty":-25.841025,"median":-7.941139,"eighty":-2.038504,"marketCap":69040264},{"date":"2023-11-24","current":-17.063157,"twenty":-25.825214,"median":-7.941139,"eighty":-2.038504,"marketCap":69071661},{"date":"2023-12-01","current":-17.063157,"twenty":-25.825214,"median":-7.941139,"eighty":-2.039391,"marketCap":69071661},{"date":"2023-12-08","current":-16.966208,"twenty":-25.825214,"median":-7.949267,"eighty":-2.04294,"marketCap":68679208},{"date":"2023-12-15","current":-16.869258,"twenty":-25.825214,"median":-7.949267,"eighty":-2.04294,"marketCap":68286755},{"date":"2023-12-22","current":-17.257057,"twenty":-25.819944,"median":-7.957396,"eighty":-2.044072,"marketCap":69856566},{"date":"2023-12-29","current":-16.966208,"twenty":-25.804132,"median":-7.96146,"eighty":-2.047469,"marketCap":68679208},{"date":"2024-01-05","current":-17.063157,"twenty":-25.798862,"median":-7.965524,"eighty":-2.050085,"marketCap":69071661},{"date":"2024-01-12","current":-16.384509,"twenty":-25.798862,"median":-8.046207,"eighty":-2.052312,"marketCap":66324492},{"date":"2024-01-19","current":-17.450956,"twenty":-25.793592,"median":-8.111634,"eighty":-2.052312,"marketCap":70641471},{"date":"2024-01-26","current":-19.293002,"twenty":-25.77251,"median":-8.118962,"eighty":-2.052476,"marketCap":78098071},{"date":"2024-02-02","current":-19.370562,"twenty":-25.77251,"median":-8.135616,"eighty":-2.054844,"marketCap":78412033},{"date":"2024-02-09","current":-17.935705,"twenty":-25.77251,"median":-8.143943,"eighty":-2.061683,"marketCap":72603734},{"date":"2024-02-16","current":-6.45394,"twenty":-25.77251,"median":-8.143943,"eighty":-2.06328,"marketCap":85947123},{"date":"2024-02-23","current":-5.95295,"twenty":-25.77251,"median":-8.139779,"eighty":-2.069667,"marketCap":79275429},{"date":"2024-03-01","current":-5.894009,"twenty":-25.77251,"median":-8.118962,"eighty":-2.069745,"marketCap":78490524},{"date":"2024-03-08","current":-6.33606,"twenty":-25.746157,"median":-8.111634,"eighty":-2.069745,"marketCap":84377313},{"date":"2024-03-15","current":-6.12977,"twenty":-25.746157,"median":-8.110635,"eighty":-2.075795,"marketCap":81630144},{"date":"2024-03-22","current":-5.894009,"twenty":-25.746157,"median":-7.969588,"eighty":-2.077556,"marketCap":78490524},{"date":"2024-03-28","current":-5.658249,"twenty":-25.746157,"median":-7.96146,"eighty":-2.077556,"marketCap":75350903},{"date":"2024-04-05","current":-6.089301,"twenty":-25.746157,"median":-7.949267,"eighty":-2.079851,"marketCap":81091218},{"date":"2024-04-12","current":-6.392251,"twenty":-25.746157,"median":-7.949267,"eighty":-2.080425,"marketCap":85125607},{"date":"2024-04-19","current":-6.301366,"twenty":-25.746157,"median":-7.941302,"eighty":-2.084378,"marketCap":83915291},{"date":"2024-04-26","current":-6.664906,"twenty":-25.746157,"median":-7.941139,"eighty":-2.091032,"marketCap":88756558},{"date":"2024-05-03","current":-6.831529,"twenty":-25.746157,"median":-7.941139,"eighty":-2.093031,"marketCap":90975471},{"date":"2024-05-10","current":-7.133641,"twenty":-25.746157,"median":-7.937075,"eighty":-2.09797,"marketCap":98237372},{"date":"2024-05-17","current":-5.947142,"twenty":-25.746157,"median":-7.933011,"eighty":-2.099168,"marketCap":81898096},{"date":"2024-05-24","current":-4.687403,"twenty":-25.735616,"median":-7.924883,"eighty":-2.106665,"marketCap":64550224},{"date":"2024-05-31","current":-4.631011,"twenty":-25.71717,"median":-7.916755,"eighty":-2.108539,"marketCap":63773654},{"date":"2024-06-07","current":-4.631011,"twenty":-25.698723,"median":-7.908627,"eighty":-2.108539,"marketCap":63773654},{"date":"2024-06-14","current":-4.572017,"twenty":-25.693453,"median":-7.908627,"eighty":-2.108694,"marketCap":62961251},{"date":"2024-06-21","current":-4.395036,"twenty":-25.468401,"median":-7.908627,"eighty":-2.109901,"marketCap":60524041},{"date":"2024-06-28","current":-4.719502,"twenty":-25.12088,"median":-7.900499,"eighty":-2.114099,"marketCap":64992259},{"date":"2024-07-05","current":-4.778496,"twenty":-25.05128,"median":-7.900499,"eighty":-2.118551,"marketCap":65804662},{"date":"2024-07-12","current":-4.719502,"twenty":-24.832534,"median":-7.892371,"eighty":-2.121113,"marketCap":64992259},{"date":"2024-07-19","current":-3.657614,"twenty":-24.827563,"median":-7.133641,"eighty":-2.122347,"marketCap":50369000},{"date":"2024-07-26","current":-3.716608,"twenty":-24.807677,"median":-6.922415,"eighty":-2.127282,"marketCap":51181404},{"date":"2024-08-02","current":-3.421639,"twenty":-24.802706,"median":-6.876972,"eighty":-2.127282,"marketCap":47119387},{"date":"2024-08-09","current":-3.815268,"twenty":-24.78282,"median":-6.846677,"eighty":-2.12752,"marketCap":46366953},{"date":"2024-08-16","current":-3.684746,"twenty":-24.777848,"median":-6.755791,"eighty":-2.128912,"marketCap":44780715},{"date":"2024-08-23","current":-3.193179,"twenty":-24.757962,"median":-6.65758,"eighty":-2.131864,"marketCap":38806699},{"date":"2024-08-30","current":-3.323299,"twenty":-24.752991,"median":-6.543726,"eighty":-2.136653,"marketCap":40388056},{"date":"2024-09-06","current":-3.453822,"twenty":-24.733105,"median":-6.54235,"eighty":-2.136653,"marketCap":41974294},{"date":"2024-09-13","current":-2.963861,"twenty":-24.733105,"median":-6.48341,"eighty":-2.138066,"marketCap":36019801},{"date":"2024-09-20","current":-3.791172,"twenty":-24.733105,"median":-6.422546,"eighty":-2.140222,"marketCap":46074109},{"date":"2024-09-27","current":-3.454223,"twenty":-24.708248,"median":-6.392251,"eighty":-2.140222,"marketCap":41979175},{"date":"2024-10-04","current":-3.644589,"twenty":-24.708248,"median":-6.33606,"eighty":-2.145715,"marketCap":44292690},{"date":"2024-10-11","current":-3.353821,"twenty":-24.708248,"median":-6.30659,"eighty":-2.147849,"marketCap":40758992},{"date":"2024-10-18","current":-3.297195,"twenty":-24.68339,"median":-6.301366,"eighty":-2.147849,"marketCap":40070808},{"date":"2024-10-25","current":-3.26105,"twenty":-24.68339,"median":-6.271071,"eighty":-2.149776,"marketCap":39631543},{"date":"2024-11-01","current":-2.83374,"twenty":-24.68339,"median":-6.18871,"eighty":-2.155396,"marketCap":34438444},{"date":"2024-11-08","current":-2.570286,"twenty":-24.68339,"median":-6.154978,"eighty":-2.155659,"marketCap":31236684},{"date":"2024-11-15","current":-0.53693,"twenty":-24.68339,"median":-6.089301,"eighty":-2.149776,"marketCap":8708466},{"date":"2024-11-22","current":-0.63793,"twenty":-24.658533,"median":-6.04136,"eighty":-2.140222,"marketCap":10346594},{"date":"2024-11-29","current":-0.659113,"twenty":-24.658533,"median":-6.038196,"eighty":-2.136653,"marketCap":10690153},{"date":"2024-12-06","current":-0.692882,"twenty":-24.658533,"median":-6.01189,"eighty":-2.127282,"marketCap":11237855},{"date":"2024-12-13","current":-0.685207,"twenty":-24.658533,"median":-5.960536,"eighty":-2.120473,"marketCap":11113377},{"date":"2024-12-20","current":-0.675384,"twenty":-24.638647,"median":-5.923479,"eighty":-2.108539,"marketCap":10954046},{"date":"2024-12-27","current":-0.691347,"twenty":-24.633675,"median":-5.894009,"eighty":-2.099168,"marketCap":11212960},{"date":"2025-01-03","current":-0.921899,"twenty":-24.633675,"median":-5.894009,"eighty":-2.088199,"marketCap":14952273},{"date":"2025-01-10","current":-0.813837,"twenty":-24.628704,"median":-5.805599,"eighty":-2.07813,"marketCap":13199625},{"date":"2025-01-17","current":-0.787436,"twenty":-24.608818,"median":-5.672984,"eighty":-2.069745,"marketCap":12771422},{"date":"2025-01-24","current":-0.785594,"twenty":-24.608818,"median":-5.641479,"eighty":-2.061683,"marketCap":12741547},{"date":"2025-01-31","current":-0.783752,"twenty":-24.608818,"median":-5.273328,"eighty":-2.052312,"marketCap":12711672},{"date":"2025-02-07","current":-1.037635,"twenty":-24.608818,"median":-4.850134,"eighty":-2.04294,"marketCap":16829398},{"date":"2025-02-14","current":-1.074781,"twenty":-24.608818,"median":-4.719502,"eighty":-2.035122,"marketCap":17431871},{"date":"2025-02-21","current":-0.909312,"twenty":-24.608818,"median":-4.719502,"eighty":-2.025235,"marketCap":14748129},{"date":"2025-02-28","current":-0.788971,"twenty":-24.608818,"median":-4.704754,"eighty":-2.011529,"marketCap":12796317},{"date":"2025-03-07","current":-0.829494,"twenty":-24.608818,"median":-4.631011,"eighty":-1.990343,"marketCap":13453560},{"date":"2025-03-14","current":-0.766253,"twenty":-24.608818,"median":-4.631011,"eighty":-1.97541,"marketCap":12427863},{"date":"2025-03-21","current":-0.756123,"twenty":-24.608818,"median":-4.572017,"eighty":-1.958599,"marketCap":12263552},{"date":"2025-03-28","current":-0.495556,"twenty":-24.608818,"median":-4.572017,"eighty":-1.949227,"marketCap":8705924},{"date":"2025-04-04","current":-0.321418,"twenty":-24.588932,"median":-4.513024,"eighty":-1.941921,"marketCap":5646674},{"date":"2025-04-11","current":-0.369068,"twenty":-24.564075,"median":-4.468778,"eighty":-1.909443,"marketCap":6483782},{"date":"2025-04-17","current":-0.330371,"twenty":-24.559103,"median":-4.45403,"eighty":-1.89289,"marketCap":5803949},{"date":"2025-04-25","current":-0.375421,"twenty":-24.559103,"median":-4.45403,"eighty":-1.879173,"marketCap":6595396},{"date":"2025-05-02","current":-0.472453,"twenty":-24.559103,"median":-4.409785,"eighty":-1.850305,"marketCap":8300053},{"date":"2025-05-09","current":-0.435777,"twenty":-24.544189,"median":-4.365539,"eighty":-1.840115,"marketCap":7655733},{"date":"2025-05-16","current":-0.388782,"twenty":-24.534246,"median":-4.192053,"eighty":-1.818564,"marketCap":7082441},{"date":"2025-05-23","current":-0.386554,"twenty":-24.534246,"median":-3.895589,"eighty":-1.809527,"marketCap":7041854},{"date":"2025-05-30","current":-0.395466,"twenty":-24.534246,"median":-3.893589,"eighty":-1.781718,"marketCap":7204202},{"date":"2025-06-06","current":-0.406927,"twenty":-24.534246,"median":-3.83968,"eighty":-1.76216,"marketCap":7412984}],"updateTime":1749348011325}}}